Stock Track | Cidara Therapeutics Soars 5.87% on Analyst Upgrades and Positive Outlook

Stock Track

Nov 07, 2025

Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for its antifungal and antiviral therapeutics, is seeing renewed investor interest following these upbeat assessments.

Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and significantly raised the price target from $100 to $135. This upgrade comes on the heels of Stringer's positive outlook on the company's progress in its CD388 Flu Program and strategic trial advancements. Additionally, H.C. Wainwright analyst Sara Nik has also maintained a Buy rating on the stock, with an even more optimistic price target of $150.

These bullish analyst views are likely driven by Cidara's recent developments in its drug pipeline, particularly the advancements in its influenza prevention program. As the company continues to make strides in its clinical trials and strategic initiatives, investors appear to be gaining confidence in Cidara's potential for future growth and success in the competitive biotechnology sector. The stock's sharp rise reflects the market's positive reaction to these analyst upgrades and the company's promising outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1149724971"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149724971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149724971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149724971","market":"sg","top_or_hot":-1,"title":"Stock Track | Cidara Therapeutics Soars 5.87% on Analyst Upgrades and Positive Outlook","media":"Stock Track","content":"<p>Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for its antifungal and antiviral therapeutics, is seeing renewed investor interest following these upbeat assessments.</p>\n\n<p>Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and significantly raised the price target from $100 to $135. This upgrade comes on the heels of Stringer's positive outlook on the company's progress in its CD388 Flu Program and strategic trial advancements. Additionally, H.C. Wainwright analyst Sara Nik has also maintained a Buy rating on the stock, with an even more optimistic price target of $150.</p>\n\n<p>These bullish analyst views are likely driven by Cidara's recent developments in its drug pipeline, particularly the advancements in its influenza prevention program. As the company continues to make strides in its clinical trials and strategic initiatives, investors appear to be gaining confidence in Cidara's potential for future growth and success in the competitive biotechnology sector. The stock's sharp rise reflects the market's positive reaction to these analyst upgrades and the company's promising outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cidara Therapeutics Soars 5.87% on Analyst Upgrades and Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cidara Therapeutics Soars 5.87% on Analyst Upgrades and Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for its antifungal and antiviral therapeutics, is seeing renewed investor interest following these upbeat assessments.</p>\n\n<p>Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and significantly raised the price target from $100 to $135. This upgrade comes on the heels of Stringer's positive outlook on the company's progress in its CD388 Flu Program and strategic trial advancements. Additionally, H.C. Wainwright analyst Sara Nik has also maintained a Buy rating on the stock, with an even more optimistic price target of $150.</p>\n\n<p>These bullish analyst views are likely driven by Cidara's recent developments in its drug pipeline, particularly the advancements in its influenza prevention program. As the company continues to make strides in its clinical trials and strategic initiatives, investors appear to be gaining confidence in Cidara's potential for future growth and success in the competitive biotechnology sector. The stock's sharp rise reflects the market's positive reaction to these analyst upgrades and the company's promising outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDTX","symbol_name":"Cidara Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1149724971","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149724971","pubTimestamp":1762527216,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDTX":"Cidara Therapeutics, Inc."},"translate_title":"个股追踪|Cidara Therapeutics大涨5.87%，因分析师上调评级及正面展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":1},"content_text":"Cidara Therapeutics (CDTX) stock is soaring 5.87% in pre-market trading on Friday, buoyed by a series of positive analyst ratings and an increased price target. The biotechnology company, known for its antifungal and antiviral therapeutics, is seeing renewed investor interest following these upbeat assessments.\nNeedham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and significantly raised the price target from $100 to $135. This upgrade comes on the heels of Stringer's positive outlook on the company's progress in its CD388 Flu Program and strategic trial advancements. Additionally, H.C. Wainwright analyst Sara Nik has also maintained a Buy rating on the stock, with an even more optimistic price target of $150.\nThese bullish analyst views are likely driven by Cidara's recent developments in its drug pipeline, particularly the advancements in its influenza prevention program. As the company continues to make strides in its clinical trials and strategic initiatives, investors appear to be gaining confidence in Cidara's potential for future growth and success in the competitive biotechnology sector. The stock's sharp rise reflects the market's positive reaction to these analyst upgrades and the company's promising outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}